MRI-PDFF作为NASH试验终点指标的无创定量评估肝脏脂肪
本文综述了磁共振成像衍生的质子密度脂肪分数(MRI-PDFF)作为无创、定量、准确的肝脏脂肪含量测量指标,可用于早期NASH试验中评估治疗反应,并讨论了其在减少样本量方面的潜在作用。目前NASH药物开发的主要障碍是治疗反应评估仍需肝活检,而MRI-PDFF有望解决这一未满足需求。
要点
- MRI-PDFF是无创、定量、准确的肝脏脂肪含量测量指标,可用于早期NASH试验评估治疗反应。
- NASH治疗反应评估目前仍需肝活检,MRI-PDFF有望作为非侵入性替代标志物。
- MRI-PDFF在早期NASH试验中可能有助于减少样本量。
核心结论
- 新兴数据支持使用MRI-PDFF作为无创、定量、准确的肝脏脂肪含量测量指标,用于评估早期NASH试验的治疗反应。
研究设计与样本
- 本文为综述,讨论MRI-PDFF作为定量无创影像学生物标志物在早期NASH试验中的作用和效用,包括潜在样本量减少。
主要发现
- NAFLD是目前全球最常见的慢性肝病病因,NASH是NAFLD的进展形式,NASH相关肝硬化已成为美国肝移植的第二大指征。
- 目前美国食品药品监督管理局尚未批准任何治疗NASH的药物。
- 治疗反应评估仍需肝活检,而肝活检是有创且主观解释的。
- MRI-PDFF作为无创、定量、准确的肝脏脂肪含量测量指标,在早期NASH试验中用于评估治疗反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide, and the progressive form of this condition, nonalcoholic steatohepatitis (NASH), has become one of the leading indications for liver transplantation. Despite intensive investigations, there are currently no United States Food and Drug Administration-approved therapies for treating NASH. A major barrier for drug development in NASH is that treatment response assessment continues to require liver biopsy, which is invasive and interpreted subjectively. Therefore, there is a major unmet need for developing noninvasive, objective, and quantitative biomarkers for diagnosis and assessment of treatment response. Emerging data support the use of magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) as a noninvasive, quantitative, and accurate measure of liver fat content to assess treatment response in early-phase NASH trials. In this review, we discuss the role and utility, including potential sample size reduction, of MRI-PDFF as a quantitative and noninvasive imaging-based biomarker in early-phase NASH trials. Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide.() NAFLD can be broadly classified into two categories: nonalcoholic fatty liver, which has a minimal risk of progression to cirrhosis, and nonalcoholic steatohepatitis (NASH), the more progressive form of NAFLD, which has a significantly increased risk of progression to cirrhosis.() Over the past two decades, NASH-related cirrhosis has become the second leading indication for liver transplantation in the United States.() For these reasons, pharmacological therapy for NASH is needed urgently. Despite intensive investigations, there are currently no therapies for treating NASH that have been approved by the United States Food and Drug Administration.().
引用
- Caussy C, Reeder SB, Sirlin CB, et al. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. Hepatology. 2018. PMID: 29356032. doi:10.1002/hep.29797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。